February 24, 2026 – Cardinal Well being launched it Biosimilars Report 2026: Enhancing Entry and Affected person Outcomes in Doctor Practiceshighlighting the substantial financial savings biosimilars have dropped at the U.S. healthcare system and the sturdy confidence suppliers have in these remedies.

The report is predicated on insights collected from 101 doctor practices throughout the nation. Almost 99% of healthcare suppliers surveyed stated they really feel snug explaining biosimilars to sufferers, underscoring the sturdy scientific belief supporting these therapies. Predictable reimbursement stays important for sustainable adoption: 68% of practices rated constant reimbursement as “essential,” whereas 59% most popular fastened low cost fashions over incremental value reductions that may disrupt reimbursement stability.

The report additionally examines a key development within the biosimilar journey: the acceleration of oncology biosimilars, which now attain a mean market share of 81% inside 5 years of launch. We anticipate FDA approval of practically 25 new biosimilars in therapeutic areas together with immunology, oncology and retina over the following two years.

Learn the total Biosimilars Report 2026.

Learn the press launch additional.